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Reach for the endoscope or the wire but not the knife for biliary stricture
after living donor liver transplantation
Re-operating on patients after liver transplantation is never a rewarding experience and can be extremely dangerous.
When a patient has undergone a living donor liver transplant (LDLT) the stakes are even higher as there may be no
opportunity for deceased donor rescue in case of vascular complications. Biliary stricture is common after living
donor liver transplant and can be difficult to manage. Many LDLT programmes are small and do not have the case
experience to manage such complications with complete confidence. It is really important therefore to learn from
centres like St Mary’s Hospital, Seoul, Korea who have a vast experience. In this edition of HPB this centre reports its
approach to managing 160 biliary strictures occurring in almost 500 patients who received a right lobe LDLT with a
duct to duct anastomosis. The greatest single risk for development of biliary stricture was a post transplant bile leak
and urgent surgery was also associated with greater risk. The authors have shown that using a variety of techniques
such as ERCP, PTBD or combinations of these procedures it is possible to manage almost all such strictures. The
avoidance of major revisional surgery is undoubtedly to the advantage of these patients. The number of failures was
remarkably small but sepsis combined with biliary stricture was associated with a small number of deaths. The value
of these interventional approaches is shown by the observation that overall survival was not significantly different
between patients with and without a biliary stricture and in both cases this exceeded 80% at 5 years.
Stephen J Wigmore
Neoadjuvant therapy for hilar cholangiocarcinoma- Is a new
approach required?
Successful surgical resection for hilar cholangiocarcinoma remains a difficult proposition due to the tumour
location, pattern of tumour spread and technical limitations associated with surgery. Resection with a positive
margin offers the patient little more than palliation alone, yet it is not an uncommon outcome for many patients
following resection. In this issue of HPB, Grendar et al. present a systematic review on the role of neoadjuvant
therapy for hilar cholangiocarcinoma. The specific aim of this paper was to discuss the clinical relevance of
neoadjuvant therapy. The authors identified only 10 papers which met the appropriate inclusion criteria, 3 case
reports, 3 retrospective reviews and 4 prospective phase I or II studies. The three options used in the neoadjuvant
setting included photodynamic, radiation and chemo therapy. As can be surmised from the preceding précis the
level of evidence to support the use of neoadjuvant therapy was very limited and graded as level IV.What is striking
as one reads through this review is the heterogeneity of so many factors within the studies. This includes definitions
of resectability, tumour types, treatments and defined end points particularly resection margins. In addition the
number of patients involved remains a small fraction of those presenting with hilar cholangiocarcinoma. No single
centre will be able to run randomised trials to answer the questions required. Would the profession be better to
consider a different approach? Firstly definitions need to be standardised. Could an international registry with a
treatment protocol, similar to the concept used by paediatric teams for rare tumours, be used as a starting point and
the standard of care? Is this a role for the IHPBA? Could consensus be achieved? How could ethical issues across
international borders be overcome? Answers to these questions are not easy, yet simply doing more of the same
would seem unlikely to significantly advance the probability of a successful outcome for patients with hilar
cholangiocarcinoma.
Saxon Connor
Determining which PNETs are worse than most
Pancreatic neuroendocrine tumours (PNETs) are often indolent, but not always. Aggressive PNET biology (early
invasion, metastases) typically becomes evident once post-operative histological indicators (grade, Ki-67 prolifera-
tive index, mitoses, necrosis) become available. The question arises as to whether aggressive multidisciplinary
treatment strategies could be better applied from the outset of treatment. Of course, but how can we know?We lack
reliable pre-treatment indicators of aggressive PNET biology. Worhunsky et al. review 146 PNET patients whose
well-differentiated PNETs were surgically resected over an 11 year period. They did not include high-grade PNETs
in this retrospective analysis, and ultimately evaluated preoperative imaging against clinical outcomes in 118
patients. On contrast-enhanced CT imaging, the majority of tumours either hyper-enhanced (68%) or iso-
enhanced (10%). A full 22% (26 pts), however, hypo-enhanced. On deeper analysis, these tumours were larger, were
more often higher grade, and more often associated with lymph node and synchronous liver metastases. And yes,
hypo-enhancing PNETs were associated with significantly worse survival after resection than the others. In fact, on
multivariate analysis of factors available preoperatively, only CT hypo-enhancement was predictive of worse sur-
vival. This study reaffirms the few available pilot studies indicating a potential predictive role for imaging in
aggressive PNETs. Through the omnipresence of contrast CT, we may soon be able to apply anti-angiogenesis agents
and proper resection strategies better aligned to aggressive PNETs. Many believe we have not achieved this to date.
Critics will point to inconsistencies in imaging techniques, but it seems these can be standardized and validated
across institutions. We should build on these findings, and going forward, not allow the train to leave the station.
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